Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris (Nasdaq: VTRS) will participate in two investor events in November 2025. The company will appear in a fireside chat at the UBS Global Healthcare Conference on November 11, 2025 at 8:45 a.m. ET, and in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 11:30 a.m. GMT / 6:30 a.m. ET. Investors and the public can listen live and access archived sessions at investor.viatris.com for a limited time after each event.

Viatris (Nasdaq: VTRS) was named to Forbes' World's Best Employers 2025, marking the company's fifth consecutive year on the list. The ranking, compiled by Forbes and Statista, surveyed more than 300,000 participants across 50 countries and included 900 companies.

Viatris highlighted workplace priorities such as wellbeing, inclusivity, learning and development, and noted prior recognitions including TIME's World's Most Sustainable Companies 2024 and Forbes' World's Top Companies for Women 2024. More information is available on Viatris' careers site and its 2024 Sustainability Report.

Viatris Inc. (NASDAQ: VTRS) has scheduled its third quarter 2025 financial results announcement for Thursday, November 6, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly performance.

Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay will be available on the company's website following the presentation.

Viatris (NASDAQ: VTRS) has appointed Andrew Enrietti as Chief Administrative and Transformation Officer in a newly created position. Enrietti, who previously served as Chief People Officer, will oversee multiple key functions including Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate.

With over 20 years of career experience, including 10 years at Viatris and its legacy companies, Enrietti brings expertise in financial services, M&A, talent strategy, and organizational effectiveness. The appointment aims to centralize leadership of the company's digital, cultural, and structural transformation initiatives to accelerate strategic evolution.

Viatris (NASDAQ:VTRS) has received FDA approval for the first generic version of Iron Sucrose Injection, USP, used to treat iron deficiency anemia in chronic kidney disease patients. The product will be available in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.

The company secured Competitive Generic Therapy (CGT) designation for two strengths, granting 180 days of exclusivity. The reference drug, Venofer®, had annual U.S. sales of $515M as of June 2025. This approval demonstrates Viatris' capabilities in developing complex generic medicines and strengthens its injectable pipeline, which includes other iron replacement products like ferric carboxymaltose injection.

Viatris (NASDAQ:VTRS) reported strong Q2 2025 results, with total revenues of $3.58 billion, down 6% year-over-year but exceeding expectations. The company's adjusted EPS reached $0.62, while adjusted EBITDA was $1.1 billion. Despite challenges, Viatris demonstrated resilience across its global business segments.

Key highlights include positive results from five Phase 3 clinical trials and significant capital returns to shareholders totaling $630 million year-to-date, including $350 million in share buybacks. The company reiterated its 2025 financial guidance, expecting to perform in the top half of the range for total revenues and adjusted EPS.

Regional performance showed strength in Greater China with 9% growth, while other markets faced some headwinds. The company continues to advance its late-stage pipeline and maintains its commitment to strategic growth initiatives for 2026 and beyond.

Viatris (NASDAQ:VTRS) has announced its latest quarterly dividend declaration. The company's Board of Directors has declared a dividend of $0.12 per share on August 4, 2025. The dividend will be paid on September 15, 2025, to shareholders who hold Viatris stock as of the close of business on August 22, 2025.

Viatris (NASDAQ: VTRS) has appointed David Simmons to its Board of Directors, bringing significant pharmaceutical industry and executive leadership experience. Simmons' notable career includes serving as CEO of Caliber Holdings Corporation, Operating Partner at Hellman & Friedman, and Chairman and CEO of PPD, Inc., where he led a 30,000-employee workforce and tripled the company's enterprise value, culminating in its $17.4 billion sale to Thermo Fisher Scientific in 2021.

Previously at Pfizer, Simmons served as President and General Manager of both the Established Products Unit and Emerging Markets division, managing 20,000 employees and 30% of Pfizer's global sales. His board experience includes positions at Cordis, Curia Global, Launch Therapeutics, Medline Industries, and Owens & Minor.

Viatris (Nasdaq: VTRS) announced the presentation of five scientific abstracts at the upcoming PAINWeek 2025 conference, showcasing data from its Phase 3 program for a novel fast-acting meloxicam formulation (MR-107A-02) in treating moderate-to-severe acute surgical pain.

The presentations, scheduled for September 2-5, 2025, in Las Vegas, will feature results from two pivotal studies in herniorrhaphy and bunionectomy surgery models. The data includes pharmacokinetics, efficacy, safety, and opioid use reduction findings. Four abstracts will have live presentations on September 4, while one will be a poster-only presentation.